|Bid||0.0000 x 0|
|Ask||0.0000 x 0|
|Day's range||3.1280 - 3.2527|
|52-week range||2.8550 - 8.5650|
|Beta (5Y monthly)||0.93|
|PE ratio (TTM)||N/A|
|Earnings date||06 Nov 2023 - 10 Nov 2023|
|Forward dividend & yield||N/A (N/A)|
|1y target est||N/A|
CRISPR Therapeutics (NASDAQ: CRSP) and Bluebird Bio (NASDAQ: BLUE) are at the forefront of developing gene therapies, yet the shares of both companies have underperformed the market over the last 12 months. CRISPR Therapeutics doesn't have any approved treatments on the market yet, but that'll change soon enough, which is the crux of the thesis in favor of it being a great growth stock. Through its partnership with Vertex Pharmaceuticals, it's aiming to commercialize the gene therapy exa-cel, which was developed to provide a functional cure for both beta-thalassemia and sickle cell disease.
Gene editing is a relatively new technology that allows scientists to modify an organism's DNA. Two companies that are hard at work in this field are Bluebird Bio (NASDAQ: BLUE) and CRISPR Therapeutics (NASDAQ: CRSP). Bluebird Bio currently has two approved gene-editing therapies on the market.
Investors looking for stocks that can put up dramatic gains in a short amount of time naturally flock to biotech stocks. Up and down Wall Street, the investment bank analysts have been telling anyone who'll listen to buy these biotech stocks before they soar. The average price target on these stocks suggests some dramatic gains could be up ahead.